While investigations into the drug are stopping in Alzheimer’s disease, the therapy is now being evaluated in TSC-related ...

The company ended 2024 with just under $127 million in cash reserves, and nothing in its pipeline beyond the Alzheimer's ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).

Shares of Cassava Sciences SAVA plunged 32.1% on Tuesday after the company announced that its lead pipeline candidate, ...

(Reuters) -Cassava Sciences said on Tuesday its Alzheimer's drug simufilam, which has been at the center of regulatory ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

We are disappointed that the results of REFOCUS-ALZ and RETHINK-ALZ showed no treatment benefit for patients with mild-to-moderate Alzheimer’s ...

SAVA and ALNY are in the spotlight this week following a study failure and label expansion of lead drug, respectively.

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...